NEW YORK (Reuters Health) – Long-term improvement in glycemic control seen with real-time continuous glucose monitoring (CGM) is similar whether used in a patient self-management protocol or in…
NEW YORK (Reuters Health) – Cigarette smoking enhanced the effects of clopidogrel in a study of diabetics with coronary artery disease. Accordingly, smokers were less likely to experience…
NEW YORK (Reuters Health) – A Canadian study confirms an increased risk of uveitis and scleritis in first-time users of oral bisphosphonates. “Patients taking bisphosphonates must be familiar…
NEW YORK (Reuters Health) – The investigational GLP-1 receptor antagonist lixisenatide significantly reduces postprandial glucose excursions and HbA1c in patients with type 2 diabetes who have not been…
NEW YORK (Reuters Health) – In patients with type 2 diabetes whose glucose levels are inadequately controlled on high doses of insulin, the addition of dapagliflozin improves HbA1c…
NEW YORK (Reuters Health) – Iron-deficiency anemia can lead to high glycosylated hemoglobin (HbA1c) concentrations that do not reflect glycemic parameters, an Indian study has shown. “The use…
NEW YORK (Reuters Health) – In patients with type 2 diabetes, glycemic control is better and weight loss is sustained up to 84 weeks with exenatide once weekly…
NEW YORK (Reuters Health) – Increases in fasting blood sugar levels are often seen in patients starting niacin, sometimes to a level that suggests new onset of type…
NEW YORK (Reuters Health) – Cabergoline in combination with low-dose pegvisomant is effective in treating patients with active acromegaly, researchers from UK report in the January 25th online…
NEW YORK (Reuters Health) – Results of a study confirm that treatment with dapagliflozin helps patients with type 2 diabetes lose weight in addition to improving their blood…